BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialChronic hypoxia and rat lung development: analysis by morphometry and directed microarrayPulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.Role of oxidative stress and NFkB in hypoxia-induced pulmonary edema.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Cyclic nucleotide signalling in kidney fibrosis.Therapeutic approaches using nitric oxide in infants and children.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Maternal PUFA ω-3 Supplementation Prevents Neonatal Lung Injuries Induced by Hyperoxia in Newborn Rats.Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.The pulmonary circulation in neonatal respiratory failure.Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia.Emerging therapies for pulmonary arterial hypertension.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Update on PPHN: mechanisms and treatment.Riociguat for the treatment of pulmonary hypertension.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indicationsRiociguat for the treatment of pulmonary hypertension.Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension.Effects of FHL1 and P21 on hypoxia-induced pulmonary vascular remodeling in neonatal rats.BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats.Fetal pulmonary vascular remodeling in a rat model induced by hypoxia and indomethacin.Signaling molecules in the fetal rabbit model for congenital diaphragmatic hernia.The Ischemic Immature Brain: Views on Current Experimental Models
P2860
Q24656131-BA940B9F-EE17-479E-A3A5-EBA40F125359Q28565830-709897EF-BB82-4D47-AE28-FFCA699DF32DQ34212268-C5B2680C-2AAF-419B-99D2-804259959A7CQ34594492-8BBE0494-6731-4A1C-B1C2-FEDDD7166F23Q35010064-44006733-8525-4E90-9CB9-7E3CBA10BF30Q35075847-74143CC5-0F78-41F1-ACE2-DA078AD3451EQ35138860-83F3DDA3-D423-4CCC-8825-C1919EB8CF02Q35165230-D25E409F-345A-4BCC-9DE0-92616B76288CQ35740400-A6D65EC3-4438-412A-B093-41647E9C6E0EQ36184205-DFD0E548-EC21-4670-8C58-18E8BC1F2C9FQ36330594-F6DD94C4-5FF1-47C2-9AB7-E9C85F2928D5Q36380981-292E9549-32C7-4818-9AD7-A805916E0341Q36687766-2ABCCF4C-A558-4660-80C4-67ABA4931B85Q36775777-D346054A-1F7E-4BCA-94A6-4811266A8A03Q36821361-620B9383-9DD9-48C7-81EE-C7AE8F7E87B1Q37420916-11F8A025-E5CE-41AC-BFB5-DF86B569A94DQ37617591-C153BEEA-42D0-41E1-986D-C97E7403488AQ37851516-8FCC2C16-561F-4C13-8EC2-BB055FAFB6D5Q38000562-3862D8A5-3B9C-47AC-83D2-2A94D43BEE93Q38093420-611F6BA8-CC6A-469F-BAA0-73F249BE2484Q38645382-59A5FD5A-BCC8-44DC-A8D2-380EEC688052Q38818645-9F923D71-B6AA-4CC1-9061-0ADE0817AE02Q38887162-2F09D1A1-6997-4A99-81C1-F65C82CF9E2FQ42675830-9889378D-774B-4D56-9240-E566A93D90B9Q45664565-70BF8F58-3405-4D7F-9F0C-AECCDED1B26BQ48203360-FE246BB7-BB01-42B1-B23E-E9AAF72B26B3Q51815503-D69C2F3F-470F-4A3B-A395-6201C3577D05Q58694155-262B0866-79F8-45F1-AAC7-3DF8867F9222
P2860
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats
description
im Januar 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 19 March 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2006
@uk
name
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@en
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@nl
type
label
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@en
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@nl
prefLabel
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@en
BAY 41-2272, a Direct Activato ...... ronic Hypoxia in Neonatal Rats
@nl
P2093
P2860
P356
P1433
P1476
BAY 41-2272, a direct activato ...... ronic hypoxia in neonatal rats
@en
P2093
Anette M Kunig
Gregory J Seedorf
Neil E Markham
Steven H Abman
Vivek Balasubramaniam
P2860
P304
P356
10.1159/000092518
P407
P577
2006-03-19T00:00:00Z